Table 1.
Study characteristics.
| Study | Patients | Lesions | BC | DCIS | Median age (range) | Projection used | Criteria evaluated | Inclusion criteria | Exposure (Gy) | Contrast media |
|---|---|---|---|---|---|---|---|---|---|---|
| Brandan 2016 [26] | 18 | 18 | 11 | 1 | 52 | CC | CE | BI-RADS 4–5 on Mx | 6 | Optiray 300 |
| Diekmann 2011]28] | 70 | 80 | 30 | 5 | 55 | CC | CE + morphology | Suspicious lesion on Mx, US, MRI | 1.76 | Ultravist 370 |
| Dromain 2011]27] | 120 | 133 | 80 | NR | 56 (27–86) | CC MLO | CE + morphology | Recall from screening + Suspicious lesion on Mx, US, MRI | 0.7–3.6 | Xenetix 300 |
| Lewin 2003 [29] | 26 | 26 | 14 | 1 | 51 | MLO | CE | Suspicious lesion on Mx | 0.7 | Omnipaque 350 |
| Łuczyńska 2016 [30] | 193 | 225 | 143 | 16 | 55 | CC MLO | CE + morphology | Suspicious lesion on Mx | NR | NR |
| Jong 2003 [31] | 22 | 22 | 10 | 1 | NR (40–74) | CC | CE + morphology | Suspicious lesion on Mx, US | NR | Omnipaque 300 |
| Tohamey 2018 [32] | NR | 178 | 104 | 6 | 46 | Unclear | CE + morphology | Unclear | NR | NR |
| Xing 2019 [33] | 235 | 263 | 177 | 6 | NR | CC MLO | CE + morphology | Suspicious lesion on US or clinical | NR | Iohexol |
Legend: BC breast cancer DCIS ductal carcinoma in situ Gy Grey CC cranio-caudal CE contrast enhancement Mx mammography US ultrasound MRI magnetic resonance imaging MLO mediolateral oblique NR not reported.